Gene mutations in gastric cancer: a review of recent next-generation sequencing studies

Tumor Biology

Volumn 36, Issue 10, 2015, Pages 7385-7394

  Lin, Y ^a   Wu, Z ^a   Guo, W ^a,c   Li, J ^b  

^a FUDAN UNIVERSITY   (China)

^b Shanghai Tianyou Hospital Affiliated to Tongji University   (China)

^c FUDAN UNIVERSITY SHANGHAI CANCER CENTER   (China)

Author keywords

Gastric cancer; Gene mutation; Next generation sequencing

Indexed keywords

APC PROTEIN; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPIDERMAL GROWTH FACTOR RECEPTOR 3; PROTEIN TYROSINE KINASE; RHOA GUANINE NUCLEOTIDE BINDING PROTEIN; UVOMORULIN; TUMOR PROTEIN;

APC GENE; ARID1A GENE; CELL ADHESION; CELL MOTILITY; CHROMATIN ASSEMBLY AND DISASSEMBLY; CLASSIFICATION; CTNNA1 GENE; CTNNB1 GENE; CYTOSKELETON; ERBB1 GENE; ERBB2 GENE; ERBB3 GENE; FAT4 GENE; GENE; GENE IDENTIFICATION; GENE MUTATION; GENETIC ASSOCIATION; GENETIC PARAMETERS; GENOME INTEGRITY; HUMAN; MAP3K4 GENE; MOLECULAR CLASSIFICATION; MUTATIONAL ANALYSIS; NEXT GENERATION SEQUENCING; PIK3CA GENE; PRIORITY JOURNAL; RECEPTOR TYROSINE KINASE PATHWAY; REVIEW; RHOA GENE; RNF43 GENE; SIGNAL TRANSDUCTION; STOMACH CANCER; TUMOR SUPPRESSOR GENE; WNT SIGNALING PATHWAY; GENETICS; HIGH THROUGHPUT SEQUENCING; MUTATION; PROCEDURES; STOMACH TUMOR;

HIGH-THROUGHPUT NUCLEOTIDE SEQUENCING; HUMANS; MUTATION; NEOPLASM PROTEINS; STOMACH NEOPLASMS;

EID: 84944279839     PISSN: 10104283     EISSN: 14230380     Source Type: Journal    
DOI: 10.1007/s13277-015-4002-1     Document Type: Review

References (77)

1. McLean MH, El-Omar EM. Genetics of gastric cancer. Nat Rev Gastroenterol Hepatol. 2014;11(11):664–74. doi:10.1038/nrgastro.2014.143.
2. Lauren P. The Two histological main types of gastric carcinoma: diffuse and so-called intestinal-type carcinoma. An attempt at a histo-clinical classification. Acta Pathol Microbio Scand. 1965;64:31–49.
3. Perou CM, Sorlie T, Eisen MB, van de Rijn M, Jeffrey SS, Rees CA, et al. Molecular portraits of human breast tumours. Nature. 2000;406(6797):747–52. doi:10.1038/35021093.
4. Wilke H, Muro K, Van Cutsem E, Oh SC, Bodoky G, Shimada Y, et al. Ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (RAINBOW): a double-blind, randomised phase 3 trial. Lancet Oncol. 2014;15(11):1224–35. doi:10.1016/s1470-2045(14)70420-6.
5. Fuchs CS, Tomasek J, Yong CJ, Dumitru F, Passalacqua R, Goswami C, et al. Ramucirumab monotherapy for previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (REGARD): an international, randomised, multicentre, placebo-controlled, phase 3 trial. Lancet. 2014;383(9911):31–9. doi:10.1016/s0140-6736(13)61719-5.
6. Qin S. Phase III study of apatinib in advanced gastric cancer: a randomized, double-blind, placebo-controlled trial. J Clin Oncol. 2014;32(15 Suppl):abstr 4003.
7. Lordick F, Kang YK, Chung HC, Salman P, Oh SC, Bodoky G, et al. Capecitabine and cisplatin with or without cetuximab for patients with previously untreated advanced gastric cancer (EXPAND): a randomised, open-label phase 3 trial. Lancet Oncol. 2013;14(6):490–9. doi:10.1016/s1470-2045(13)70102-5.
8. Meyerson M, Gabriel S, Getz G. Advances in understanding cancer genomes through second-generation sequencing. Nat Rev Genet. 2010;11(10):685–96.
9. Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell. 2011;144(5):646–74. doi:10.1016/j.cell.2011.02.013.
10. Lane DP. Cancer. p53, guardian of the genome. Nature. 1992;358(6381):15–6. doi:10.1038/358015a0.
11. Wang K, Kan J, Yuen ST, Shi ST, Chu KM, Law S, et al. Exome sequencing identifies frequent mutation of ARID1A in molecular subtypes of gastric cancer. Nat Genet. 2011;43(12):1219–23. doi:10.1038/ng.982.
12. Zang ZJ, Cutcutache I, Poon SL, Zhang SL, McPherson JR, Tao J, et al. Exome sequencing of gastric adenocarcinoma identifies recurrent somatic mutations in cell adhesion and chromatin remodeling genes. Nat Genet. 2012;44(5):570–4. doi:10.1038/ng.2246.
13. Cancer Genome Atlas Research Network. Comprehensive molecular characterization of gastric adenocarcinoma. Nature. 2014;513(7517):202–9. doi:10.1038/nature13480.
14. Kakiuchi M, Nishizawa T, Ueda H, Gotoh K, Tanaka A, Hayashi A, et al. Recurrent gain-of-function mutations of RHOA in diffuse-type gastric carcinoma. Nat Genet. 2014;46(6):583–7. doi:10.1038/ng.2984.
15. Wang K, Yuen ST, Xu J, Lee SP, Yan HH, Shi ST, et al. Whole-genome sequencing and comprehensive molecular profiling identify new driver mutations in gastric cancer. Nat Genet. 2014;46(6):573–82. doi:10.1038/ng.2983.
16. Chang VY, Federman N, Martinez-Agosto J, Tatishchev SF, Nelson SF. Whole exome sequencing of pediatric gastric adenocarcinoma reveals an atypical presentation of Li-Fraumeni syndrome. Pediatr Blood Cancer. 2013;60(4):570–4. doi:10.1002/pbc.24316.
17. Cristescu R, Lee J, Nebozhyn M, Kim KM, Ting JC, Wong SS, et al. Molecular analysis of gastric cancer identifies subtypes associated with distinct clinical outcomes. Nat Med. 2015;21(5):449–56. doi:10.1038/nm.3850.
18. Holbrook JD, Parker JS, Gallagher KT, Halsey WS, Hughes AM, Weigman VJ, et al. Deep sequencing of gastric carcinoma reveals somatic mutations relevant to personalized medicine. J Transl Med. 2011;9:119. doi:10.1186/1479-5876-9-119.
19. Kang G, Hwang WC, Do IG, Wang K, Kang SY, Lee J, et al. Exome sequencing identifies early gastric carcinoma as an early stage of advanced gastric cancer. PloS One. 2013;8(12), e82770. doi:10.1371/journal.pone.0082770.
20. Lee J, van Hummelen P, Go C, Palescandolo E, Jang J, Park HY, et al. High-throughput mutation profiling identifies frequent somatic mutations in advanced gastric adenocarcinoma. PloS One. 2012;7(6):e38892. doi:10.1371/journal.pone.0038892.
21. Wong SS, Kim KM, Ting JC, Yu K, Fu J, Liu S, et al. Genomic landscape and genetic heterogeneity in gastric adenocarcinoma revealed by whole-genome sequencing. Nat Commun. 2014;5:5477. doi:10.1038/ncomms6477.
22. Kim TM, Jung SH, Kim MS, Baek IP, Park SW, Lee SH, et al. The mutational burdens and evolutionary ages of early gastric cancers are comparable to those of advanced gastric cancers. J Pathol. 2014;234(3):365–74. doi:10.1002/path.4401.
23. Kim YH, Liang H, Liu X, Lee JS, Cho JY, Cheong JH, et al. AMPKα modulation in cancer progression: multilayer integrative analysis of the whole transcriptome in Asian gastric cancer. Cancer Res. 2012;72(10):2512–21. doi:10.1158/0008-5472.can-11-3870.
24. Lee YS, Cho YS, Lee GK, Lee S, Kim YW, Jho S, et al. Genomic profile analysis of diffuse-type gastric cancers. Genome Biol. 2014;15(4):R55. doi:10.1186/gb-2014-15-4-r55.
25. Cerami E, Gao JJ, Dogrusoz U, Gross BE, Sumer SO, Aksoy BA, et al. The cBio Cancer Genomics Portal: an open platform for exploring multidimensional cancer genomics data. Cancer Discov. 2012;2(5):401–4.
26. Gao JJ, Aksoy BA, Dogrusoz U, Dresdner G, Gross B, Sumer SO, et al. Integrative analysis of complex cancer genomics and clinical profiles using the cBioPortal. Sci Signal. 2013;6(269):l1.
27. Venkitaraman AR. Cancer susceptibility and the functions of BRCA1 and BRCA2. Cell. 2002;108(2):171–82.
28. Chen K, Yang D, Li X, Sun B, Song F, Cao W, et al. Mutational landscape of gastric adenocarcinoma in Chinese: implications for prognosis and therapy. Proc Natl Acad Sci USA. 2015;112(4):1107–12. doi:10.1073/pnas.1422640112.
29. Hansford S, Kaurah P, Li-Chang H, Woo M, Senz J, Pinheiro H, et al. Hereditary diffuse gastric cancer syndrome: CDH1 mutations and beyond. JAMA Oncol. 2015;1(1):23–32. doi:10.1001/jamaoncol.2014.168.
30. Kandoth C, McLellan MD, Vandin F, Ye K, Niu B, Lu C, et al. Mutational landscape and significance across 12 major cancer types. Nature. 2013;502(7471):333–9. doi:10.1038/nature12634.
31. Saha A, Wittmeyer J, Cairns BR. Chromatin remodelling: the industrial revolution of DNA around histones. Nat Rev Mol Cell Biol. 2006;7(6):437–47. doi:10.1038/nrm1945.
32. Yaniv M. Chromatin remodeling: from transcription to cancer. Cancer Genet. 2014;207(9):352–7. doi:10.1016/j.cancergen.2014.03.006.
33. Jones S, Li M, Parsons DW, Zhang X, Wesseling J, Kristel P, et al. Somatic mutations in the chromatin remodeling gene ARID1A occur in several tumor types. Hum Mutat. 2012;33(1):100–3. doi:10.1002/humu.21633.
34. Jones S, Wang TL, Shih Ie M, Mao TL, Nakayama K, Roden R, et al. Frequent mutations of chromatin remodeling gene ARID1A in ovarian clear cell carcinoma. Science. 2010;330(6001):228–31. doi:10.1126/science.1196333.
35. Wiegand KC, Shah SP, Al-Agha OM, Zhao Y, Tse K, Zeng T, et al. ARID1A mutations in endometriosis-associated ovarian carcinomas. N Engl J Med. 2010;363(16):1532–43. doi:10.1056/NEJMoa1008433.
36. Nagl Jr NG, Wang X, Patsialou A, Van Scoy M, Moran E. Distinct mammalian SWI/SNF chromatin remodeling complexes with opposing roles in cell-cycle control. EMBO J. 2007;26(3):752–63. doi:10.1038/sj.emboj.7601541.
37. Weissman B, Knudsen KE. Hijacking the chromatin remodeling machinery: impact of SWI/SNF perturbations in cancer. Cancer Res. 2009;69(21):8223–30. doi:10.1158/0008-5472.CAN-09-2166.
38. Je EM, Lee SH, Yoo NJ, Lee SH. Mutational and expressional analysis of MLL genes in gastric and colorectal cancers with micro satellite instability. Neoplasma. 2013;60(2):188–95. doi:10.4149/neo_2013_025.
39. Fitzgerald RC, Hardwick R, Huntsman D, Carneiro F, Guilford P, Blair V, et al. Hereditary diffuse gastric cancer: updated consensus guidelines for clinical management and directions for future research. J Medical Genet. 2010;47(7):436–44. doi:10.1136/jmg.2009.074237.
40. Majewski IJ, Kluijt I, Cats A, Scerri TS, de Jong D, Kluin RJ, et al. An α-E-catenin (CTNNA1) mutation in hereditary diffuse gastric cancer. J Pathol. 2013;229(4):621–9. doi:10.1002/path.4152.
41. Tenedini E, Bernardis I, Artusi V, Artuso L, Roncaglia E, Guglielmelli P, et al. Targeted cancer exome sequencing reveals recurrent mutations in myeloproliferative neoplasms. Leukemia. 2014;28(5):1052–9. doi:10.1038/leu.2013.302.
42. Yu J, Wu WK, Li X, He J, Li XX, Ng SS, et al. Novel recurrently mutated genes and a prognostic mutation signature in colorectal cancer. Gut. 2015;64(4):636–45. doi:10.1136/gutjnl-2013-306620.
43. Wang Y. Wnt/planar cell polarity signaling: a new paradigm for cancer therapy. Mol Cancer Ther. 2009;8(8):2103–9. doi:10.1158/1535-7163.MCT-09-0282.
44. Ward CJ, Wu Y, Johnson RA, Woollard JR, Bergstralh EJ, Cicek MS, et al. Germline PKHD1 mutations are protective against colorectal cancer. Hum Genet. 2011;129(3):345–9. doi:10.1007/s00439-011-0950-8.
45. Karlsson R, Pedersen ED, Wang Z, Brakebusch C. Rho GTPase function in tumorigenesis. Biochim Biophys Acta. 2009;1796(2):91–8. doi:10.1016/j.bbcan.2009.03.003.
46. Wheeler AP, Ridley AJ. Why three Rho proteins? RhoA, RhoB, RhoC, and cell motility. Exp Cell Res. 2004;301(1):43–9. doi:10.1016/j.yexcr.2004.08.012.
47. Pan Y, Bi F, Liu N, Xue Y, Yao X, Zheng Y, et al. Expression of seven main Rho family members in gastric carcinoma. Biochem Biophys Res Commun. 2004;315(3):686–91. doi:10.1016/j.bbrc.2004.01.108.
48. Yoo HY, Sung MK, Lee SH, Kim S, Lee H, Park S, et al. A recurrent inactivating mutation in RHOA GTPase in angioimmunoblastic T cell lymphoma. Nat Genet. 2014;46(4):371–5. doi:10.1038/ng.2916.
49. Sakata-Yanagimoto M, Enami T, Yoshida K, Shiraishi Y, Ishii R, Miyake Y, et al. Somatic RHOA mutation in angioimmunoblastic T cell lymphoma. Nat Genet. 2014;46(2):171–5. doi:10.1038/ng.2872.
50. Palomero T, Couronne L, Khiabanian H, Kim MY, Ambesi-Impiombato A, Perez-Garcia A, et al. Recurrent mutations in epigenetic regulators, RHOA and FYN kinase in peripheral T cell lymphomas. Nat Genet. 2014;46(2):166–70. doi:10.1038/ng.2873.
51. Nagarajan N, Bertrand D, Hillmer AM, Zang ZJ, Yao F, Jacques PE, et al. Whole-genome reconstruction and mutational signatures in gastric cancer. Genome Biol. 2012;13(12):R115. doi:10.1186/gb-2012-13-12-r115.
52. Lochhead PA, Wickman G, Mezna M, Olson MF. Activating ROCK1 somatic mutations in human cancer. Oncogene. 2010;29(17):2591–8. doi:10.1038/onc.2010.3.
53. Clevers H, Nusse R. Wnt/β-catenin signaling and disease. Cell. 2012;149(6):1192–205. doi:10.1016/j.cell.2012.05.012.
54. Giles RH, van Es JH, Clevers H. Caught up in a Wnt storm: Wnt signaling in cancer. Biochim Biophys Acta. 2003;1653(1):1–24.
55. Wu J, Jiao Y, Dal Molin M, Maitra A, de Wilde RF, Wood LD, et al. Whole-exome sequencing of neoplastic cysts of the pancreas reveals recurrent mutations in components of ubiquitin-dependent pathways. Proc Nat Acad Sci USA. 2011;108(52):21188–93. doi:10.1073/pnas.1118046108.
56. Jiang X, Hao HX, Growney JD, Woolfenden S, Bottiglio C, Ng N, et al. Inactivating mutations of RNF43 confer Wnt dependency in pancreatic ductal adenocarcinoma. Proc Nat Acad Sci USA. 2013;110(31):12649–54. doi:10.1073/pnas.1307218110.
57. Ryland GL, Hunter SM, Doyle MA, Rowley SM, Christie M, Allan PE, et al. RNF43 is a tumour suppressor gene mutated in mucinous tumours of the ovary. J Pathol. 2013;229(3):469–76. doi:10.1002/path.4134.
58. Giannakis M, Hodis E, Jasmine Mu X, Yamauchi M, Rosenbluh J, Cibulskis K, et al. RNF43 is frequently mutated in colorectal and endometrial cancers. Nat Genet. 2014;46(12):1264–6. doi:10.1038/ng.3127.
59. Sakamoto H, Kuboki Y, Hatori T, Yamamoto M, Sugiyama M, Shibata N, et al. Clinicopathological significance of somatic RNF43 mutation and aberrant expression of ring finger protein 43 in intraductal papillary mucinous neoplasms of the pancreas. Mod Pathol. 2015;28(2):261–7. doi:10.1038/modpathol.2014.98.
60. Koo B-K, Spit M, Jordens I, Low TY, Stange DE, van de Wetering M, et al. Tumour suppressor RNF43 is a stem-cell E3 ligase that induces endocytosis of Wnt receptors. Nature. 2012;488(7413):665–9. doi:10.1038/nature11308.
61. Lin W, Kao HW, Robinson D, Kung HJ, Wu CW, Chen HC. Tyrosine kinases and gastric cancer. Oncogene. 2000;19(49):5680–9. doi:10.1038/sj.onc.1203924.
62. Lee JW, Soung YH, Seo SH, Kim SY, Park CH, Wang YP, et al. Somatic mutations of ERBB2 kinase domain in gastric, colorectal, and breast carcinomas. Clin Cancer Res. 2006;12(1):57–61. doi:10.1158/1078-0432.ccr-05-0976.
63. Moutinho C, Mateus AR, Milanezi F, Carneiro F, Seruca R, Suriano G. Epidermal growth factor receptor structural alterations in gastric cancer. BMC cancer. 2008;8:10. doi:10.1186/1471-2407-8-10.
64. Liu Z, Liu L, Li M, Wang Z, Feng L, Zhang Q, et al. Epidermal growth factor receptor mutation in gastric cancer. Pathology. 2011;43(3):234–8. doi:10.1097/PAT.0b013e328344e61b.
65. Chmielecki J, Ross JS, Wang K, Frampton GM, Palmer GA, Ali SM, et al. Oncogenic alterations in ERBB2/HER2 represent potential therapeutic targets across tumors from diverse anatomic sites of origin. Oncologist. 2015;20(1):7–12. doi:10.1634/theoncologist.2014-0234.
66. Jaiswal BS, Kljavin NM, Stawiski EW, Chan E, Parikh C, Durinck S, et al. Oncogenic ERBB3 mutations in human cancers. Cancer Cell. 2013;23(5):603–17. doi:10.1016/j.ccr.2013.04.012.
67. Choi MR, An CH, Chung YJ, Choi YJ, Yoo NJ, Lee SH. Mutational and expressional analysis of ERBB3 gene in common solid cancers. APMIS. 2014;122(12):1207–12. doi:10.1111/apm.12286.
68. Prickett TD, Agrawal NS, Wei X, Yates KE, Lin JC, Wunderlich JR, et al. Analysis of the tyrosine kinome in melanoma reveals recurrent mutations in ERBB4. Nat Genet. 2009;41(10):1127–32. doi:10.1038/ng.438.
69. Fassan M, Simbolo M, Bria E, Mafficini A, Pilotto S, Capelli P, et al. High-throughput mutation profiling identifies novel molecular dysregulation in high-grade intraepithelial neoplasia and early gastric cancers. Gastric Cancer. 2014;17(3):442–9. doi:10.1007/s10120-013-0315-1.
70. Jang JH, Shin KH, Park JG. Mutations in fibroblast growth factor receptor 2 and fibroblast growth factor receptor 3 genes associated with human gastric and colorectal cancers. Cancer Res. 2001;61(9):3541–3.
71. Vogelstein B, Kinzler KW. Cancer genes and the pathways they control. Nat Med. 2004;10(8):789–99. doi:10.1038/nm1087.
72. Zang ZJ, Ong CK, Cutcutache I, Yu W, Zhang SL, Huang D, et al. Genetic and structural variation in the gastric cancer kinome revealed through targeted deep sequencing. Cancer Res. 2011;71(1):29–39. doi:10.1158/0008-5472.CAN-10-1749.
73. Gaston D, Hansford S, Oliveira C, Nightingale M, Pinheiro H, Macgillivray C, et al. Germline mutations in MAP3K6 are associated with familial gastric cancer. PLoS Genet. 2014;10(10):e1004669. doi:10.1371/journal.pgen.1004669.
74. Liang Q, Yao X, Tang S, Zhang J, Yau TO, Li X, et al. Integrative identification of Epstein-Barr virus-associated mutations and epigenetic alterations in gastric cancer. Gastroenterology. 2014;147(6):1350–62 e4. doi:10.1053/j.gastro.2014.08.036.
75. Samuels Y, Wang Z, Bardelli A, Silliman N, Ptak J, Szabo S, et al. High frequency of mutations of the PIK3CA gene in human cancers. Science. 2004;304(5670):554. doi:10.1126/science.1096502.
76. Bader AG, Kang S, Vogt PK. Cancer-specific mutations in PIK3CA are oncogenic in vivo. Proc Natl Acad Sci USA. 2006;103(5):1475–9. doi:10.1073/pnas.0510857103.
77. Janku F, Hong DS, Fu S, Piha-Paul SA, Naing A, Falchook GS, et al. Assessing PIK3CA and PTEN in early-phase trials with PI3K/AKT/mTOR inhibitors. Cell Rep. 2014;6(2):377–87. doi:10.1016/j.celrep.2013.12.035.